Ipsen S.A. (IPSEF)
| Previous close | 117.60 |
| Open | 117.60 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 117.60 - 117.60 |
| 52-week range | 108.75 - 123.75 |
| Volume | |
| Avg. volume | 47 |
| Market cap | 9.726B |
| Beta (5Y monthly) | 0.64 |
| PE ratio (TTM) | 14.96 |
| EPS (TTM) | 7.86 |
| Earnings date | N/A |
| Forward dividend & yield | 1.28 (1.08%) |
| Ex-dividend date | 30 May 2024 |
| 1y target est | N/A |
Globe NewswireIpsen publishes its 2023 Universal Registration Document
Ipsen publishes its 2023 Universal Registration Document PARIS, FRANCE, 17 April 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty biopharmaceutical group, announces that its 2023 Universal Registration Document has been filed with the French Autorité des Marchés Financiers on 17 April 2024 and registered under the number D.24-0288. The document is available on ipsen.com and amf-france.org. Copies will also be available at Ipsen’s headquarters – 65 quai Georges Gorse, 92100 Boulogne-B
- Globe Newswire
Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital
Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers) Market: Euronext Paris ISIN Code: FR 0010259150LEI: 549300M6SGDPB4Z94P11 Date Total number of shares composing the share capital Total number of voting rights (1) 31 March 2024 83,814,526 Gross total* of voting rights: 132,107,179 Net total*
PR NewswireMarengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen
Marengo Therapeutics, Inc, a clinical-stage biotech company pioneering a new way to activate T cells that target the Vβ chain of the T cell receptor (TCR) and select the right T cell subsets against cancer, today announced that Ipsen (Euronext: IPN; ADR: IPSEY) has nominated the first clinical drug candidate (DC) of two from its multi-year strategic partnership in oncology.
